Receive alerts
Unlisted (UK)
Market Cap:
52 weeks high
52 weeks low

In brief

Arecor Limited is a biopharmaceutical company transforming patient care by bringing innovative medicines to market.  Through the enhancement of existing medicines using its  Arestat technology, the firm is developing a broad portfolio of therapies as part of our proprietary pipeline and through partnerships with leading pharmaceutical and biotech companies.  Its treatments for people living with chronic disease are designed to simplify patient care and improve medication adherence.

Deep dive We explore the investor case for growth companies


Arecor is waiting for the results from phase I clinical trials of its ultra-rapid acting insulin candidate, AT247, expected by the end of the year

Insight Widest with the analysis, Proactive gives perspectives that others don't.

Arecor punches above its weight with trials for fast-acting diabetes drugs

Investors are placing bets on a small British biotech to rival big pharma as it pushes its first diabetes drug through clinical trials

on 11/14/2019